tiprankstipranks
Trending News
More News >
Centene (CNC)
:CNC
Advertisement

Centene (CNC) AI Stock Analysis

Compare
2,908 Followers

Top Page

CNC

Centene

(NYSE:CNC)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
$37.00
▲(12.98% Upside)
Centene's overall stock score is driven by strong revenue growth and an attractive valuation, offset by operational challenges and financial pressures highlighted in the earnings call. Technical indicators suggest caution due to potential overbought conditions.
Positive Factors
Revenue Growth
Strong revenue growth indicates Centene's ability to expand its market presence and enhance its service offerings, supporting long-term business sustainability.
Medicare Advantage Progress
Progress in Medicare Advantage suggests improved operational efficiency and potential profitability, enhancing Centene's competitive position in the healthcare market.
Improved Medicaid Rate Outlook
A favorable Medicaid rate adjustment strengthens Centene's revenue base and supports future profitability, reflecting effective negotiation and strategic positioning.
Negative Factors
Low Operational Margins
Low operational margins indicate challenges in cost management and efficiency, potentially limiting profitability and financial flexibility in the long term.
Marketplace Risk Adjustment Challenge
Significant financial pressure from risk adjustment changes could impact Centene's profitability and require strategic adjustments to mitigate long-term risks.
Elevated Medical Cost Trend in Medicaid
High medical costs in Medicaid could strain Centene's resources and impact margins, necessitating strategic cost management to maintain financial health.

Centene (CNC) vs. SPDR S&P 500 ETF (SPY)

Centene Business Overview & Revenue Model

Company DescriptionCentene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
How the Company Makes MoneyCentene generates revenue primarily through the provision of healthcare services to government programs such as Medicaid and Medicare. The company earns money by receiving monthly premiums for each member enrolled in its health plans, which are paid by state and federal government agencies. Key revenue streams include Medicaid managed care, Medicare Advantage plans, and the Health Insurance Marketplace. Additionally, Centene benefits from partnerships with various states to administer Medicaid programs and engages in value-based care arrangements that incentivize cost savings and improved health outcomes. The company's growth is also supported by strategic acquisitions that expand its service offerings and member base, enhancing its overall revenue potential.

Centene Key Performance Indicators (KPIs)

Any
Any
Revenue by Product
Revenue by Product
Chart Insights
Data provided by:Main Street Data

Centene Earnings Call Summary

Earnings Call Date:Jul 25, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 28, 2025
Earnings Call Sentiment Negative
The earnings call highlighted significant challenges faced by Centene, particularly in the Marketplace and Medicaid segments, which have led to financial underperformance for the quarter and a reduced outlook for the year. However, there were positive developments in Medicare Advantage and PDP performance, as well as improved Medicaid rate adjustments.
Q2-2025 Updates
Positive Updates
Medicare Advantage Progress
Medicare Advantage business is achieving significant operational progress, running slightly favorable to expectations, on track for breakeven in 2027.
Improved 2025 Medicaid Rate Outlook
Secured better-than-expected 2025 composite rate adjustment of 5% for Medicaid, stronger than the previous expectation of 4%.
Cash Flow and Liquidity Management
Cash flow provided by operations was $1.8 billion for Q2; no further 2025 share buyback planned but open to opportunistic buybacks.
Medicare PDP Performance
Medicare PDP program is providing earnings upside relative to previous outlook, with membership at 7.8 million.
Negative Updates
Marketplace Risk Adjustment Challenge
Marketplace earnings pressured by $2.4 billion due to a change in risk adjustment transfer assumptions, with a significant morbidity shift in the market.
Elevated Medical Cost Trend in Medicaid
Medicaid portfolio health benefits ratio of 94.9% driven by behavioral health, home health, and high-cost drugs.
2025 Financial Performance
Reported an adjusted loss per share of $0.16 for Q2 2025, with full-year adjusted diluted EPS forecast reduced to approximately $1.75 from $7.25.
Marketplace Segment Utilization Increase
Higher levels of utilization in the Marketplace segment, impacting performance and contributing to financial pressure.
Company Guidance
During Centene Corporation's second quarter 2025 earnings call, the company provided detailed guidance on their financial outlook, highlighting several key metrics. They reported a second quarter adjusted per share loss of $0.16, with future expectations for the full year 2025 adjusted diluted EPS to be approximately $1.75. The call detailed the impact of a $2.4 billion full-year headwind to 2025 pretax earnings due to Marketplace morbidity shifts, alongside an additional $200 million in pretax margin pressure from anticipated increased utilization. The Medicaid Health Benefits Ratio (HBR) was notably high at 94.9% for Q2, driven by cost trends in behavioral health, home health, and high-cost drugs, with expectations for the Medicaid HBR to be about 93.5% in the second half of the year. The company projected a 5% composite rate adjustment for Medicaid for 2025 and anticipated improving Medicare and Marketplace margins in 2026. Despite challenges, Centene remains focused on enhancing profitability across its portfolio, with a strategic emphasis on repricing and operational improvements to restore profitability by 2026.

Centene Financial Statement Overview

Summary
Centene shows strong revenue growth and a stable balance sheet with moderate leverage. However, operational efficiency is a concern with low EBIT and EBITDA margins. Cash flow metrics indicate challenges in cash conversion, but there are recent improvements in free cash flow.
Income Statement
78
Positive
Centene's TTM (Trailing-Twelve-Months) data shows a robust Gross Profit Margin of 12.5% and a Net Profit Margin of 1.15%. The company demonstrated a strong Revenue Growth Rate of 9.29% from the previous year, indicating healthy expansion. However, the EBIT Margin of 1.07% and EBITDA Margin of 2.25% are relatively low, suggesting limited operational efficiency.
Balance Sheet
75
Positive
Centene's financial leverage is moderate with a Debt-to-Equity Ratio of 0.64. The company has a Return on Equity (ROE) of 7.5%, which is satisfactory but shows room for improvement. The Equity Ratio stands at 31.73%, reflecting a stable capital structure with a reasonable proportion of equity financing.
Cash Flow
65
Positive
The company's Free Cash Flow Growth Rate is positive, recovering from a negative position last year to $1.08 billion. The Operating Cash Flow to Net Income Ratio of 0.84 indicates adequate cash generation relative to net profits. However, the Free Cash Flow to Net Income Ratio of 0.53 suggests potential challenges in converting earnings into free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue178.19B163.07B154.00B144.55B125.98B111.11B
Gross Profit15.90B16.83B17.32B16.66B14.20B15.22B
EBITDA4.39B6.20B5.62B4.06B3.81B4.76B
Net Income2.05B3.31B2.70B1.20B1.35B1.81B
Balance Sheet
Total Assets86.39B82.44B84.64B76.87B78.38B68.72B
Cash, Cash Equivalents and Short-Term Investments17.28B16.68B19.65B14.39B14.66B12.38B
Total Debt17.58B19.43B18.88B21.33B22.66B18.32B
Total Liabilities58.89B55.94B58.69B52.63B51.35B42.76B
Stockholders Equity27.41B26.41B25.84B24.06B26.80B25.77B
Cash Flow
Free Cash Flow1.08B-490.00M7.25B5.26B3.29B4.63B
Operating Cash Flow1.73B154.00M8.05B6.26B4.21B5.50B
Investing Cash Flow-2.17B-1.05B-1.19B-2.92B-3.30B-6.96B
Financing Cash Flow-2.68B-2.41B-1.66B-4.20B1.36B260.00M

Centene Technical Analysis

Technical Analysis Sentiment
Positive
Last Price32.75
Price Trends
50DMA
28.92
Positive
100DMA
40.83
Negative
200DMA
50.59
Negative
Market Momentum
MACD
0.97
Negative
RSI
66.90
Neutral
STOCH
54.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNC, the sentiment is Positive. The current price of 32.75 is above the 20-day moving average (MA) of 31.13, above the 50-day MA of 28.92, and below the 200-day MA of 50.59, indicating a neutral trend. The MACD of 0.97 indicates Negative momentum. The RSI at 66.90 is Neutral, neither overbought nor oversold. The STOCH value of 54.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNC.

Centene Risk Analysis

Centene disclosed 35 risk factors in its most recent earnings report. Centene reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Centene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
95.29B20.965.86%3.48%6.27%-36.28%
73
Outperform
9.86B9.0024.55%16.12%10.99%
73
Outperform
77.04B15.7612.48%2.04%20.93%43.98%
71
Outperform
71.58B13.5312.26%2.09%10.21%-17.79%
70
Outperform
$16.06B8.107.50%12.96%-23.25%
70
Outperform
31.01B19.798.64%1.37%9.88%-7.25%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CNC
Centene
34.65
-39.47
-53.25%
CI
Cigna
290.08
-52.24
-15.26%
CVS
CVS Health
76.38
20.31
36.22%
HUM
Humana
261.97
-45.88
-14.90%
MOH
Molina Healthcare
190.71
-153.79
-44.64%
ELV
Elevance Health
323.73
-187.42
-36.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025